Key Points
- Director Ezra Friedberg sold 558 shares on April 2 for a total of $11,673.36 at an average price of $20.92 under a pre-arranged Rule 10b5-1 plan and still holds 82,027 shares (a 0.68% reduction).
- Pelthos shares were trading up about 19.5% (opened at $24.38), with a 12‑month range of $9.00–$54.29, a market cap of roughly $81.9M, negative P/E, and a high beta (~3.93), indicating volatility.
- Institutional investors own about 77.96% of the stock with several funds recently increasing stakes, and analysts show a consensus "Moderate Buy" rating with an average target of $55.
Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS - Get Free Report) Director Ezra Friedberg sold 558 shares of Pelthos Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $20.92, for a total transaction of $11,673.36. Following the completion of the sale, the director directly owned 82,027 shares of the company's stock, valued at approximately $1,716,004.84. This trade represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Pelthos Therapeutics Trading Up 19.5%
NYSEAMERICAN:PTHS opened at $24.38 on Tuesday. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.15 and a current ratio of 2.05. Pelthos Therapeutics Inc. has a 12 month low of $9.00 and a 12 month high of $54.29. The company has a market cap of $81.92 million, a P/E ratio of -1.17 and a beta of 3.93. The stock has a 50 day moving average of $22.86.
Institutional Investors Weigh In On Pelthos Therapeutics
Hedge funds have recently modified their holdings of the business. Persistent Asset Partners Ltd grew its position in shares of Pelthos Therapeutics by 150.0% during the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company's stock valued at $186,000 after acquiring an additional 3,604 shares during the period. Millennium Management LLC purchased a new position in shares of Pelthos Therapeutics during the 4th quarter valued at $343,000. Geode Capital Management LLC lifted its stake in shares of Pelthos Therapeutics by 31.9% during the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company's stock valued at $422,000 after buying an additional 3,295 shares in the last quarter. Knott David M Jr lifted its stake in shares of Pelthos Therapeutics by 215.5% during the 4th quarter. Knott David M Jr now owns 19,281 shares of the company's stock valued at $598,000 after buying an additional 13,169 shares in the last quarter. Finally, Diadema Partners LP lifted its stake in shares of Pelthos Therapeutics by 138.1% during the 4th quarter. Diadema Partners LP now owns 25,000 shares of the company's stock valued at $775,000 after buying an additional 14,502 shares in the last quarter. Institutional investors own 77.96% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on PTHS shares. Roth Mkm cut their price objective on shares of Pelthos Therapeutics from $57.00 to $55.00 and set a "buy" rating for the company in a research report on Thursday, February 26th. Piper Sandler started coverage on shares of Pelthos Therapeutics in a research report on Friday, February 27th. They set an "overweight" rating and a $48.00 price objective for the company. Zacks Research raised shares of Pelthos Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 24th. Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an "overweight" rating and a $50.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and set a $60.00 price objective on shares of Pelthos Therapeutics in a research report on Thursday, March 19th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $55.00.
View Our Latest Stock Analysis on PTHS
Pelthos Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
